Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation
- 1 March 2003
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 16 (3) , 197-201
- https://doi.org/10.1111/j.1432-2277.2003.tb00286.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER WITH THE ANTI-CD20 MONOCLONAL ANTIBODY RITUXIMAB ALONE IN AN ADULT AFTER LIVER TRANSPLANTATIONTransplantation, 2000
- Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantationThe Lancet, 1999
- EPSTEIN-BARR VIRUS-INDUCED POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERSTransplantation, 1999
- INTERFERON-?? TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1Transplantation, 1998
- Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disordersThe Lancet, 1998
- COMPLETE REMISSION AND POSSIBLE IMMUNE TOLERANCE AFTER MULTIDRUG COMBINATION CHEMOTHERAPY FOR CYCLOSPORINE-RELATED LYMPHOMA IN A RENAL TRANSPLANT RECIPIENT WITH ACUTE PANCREATITISTransplantation, 1991
- Anti–B-Cell Monoclonal Antibodies in the Treatment of Severe B-Cell Lymphoproliferative Syndrome Following Bone Marrow and Organ TransplantationNew England Journal of Medicine, 1991
- B-cell lymphoma in transplanted liverTransplant International, 1991
- Increased Incidence of Lymphoproliferative Disorder after Immunosuppression with the Monoclonal Antibody OKT3 in Cardiac-Transplant RecipientsNew England Journal of Medicine, 1990
- Cancers Complicating Organ TransplantationNew England Journal of Medicine, 1990